2020
DOI: 10.1016/j.intimp.2020.106610
|View full text |Cite
|
Sign up to set email alerts
|

PIK3R3 regulates ZO-1 expression through the NF-kB pathway in inflammatory bowel disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

4
30
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 48 publications
(34 citation statements)
references
References 27 publications
4
30
0
Order By: Relevance
“…[13] Meanwhile, the substantial inflammatory cytokines can further facilitate the progression of IBD, leading to disruption of mucosal barrier damage and loss of tight junction protein (ZO-1). [14] The M1 polarization is regulated by ROS. In the early stage of polarization, macrophages express ROS substantially.…”
Section: Discussionmentioning
confidence: 99%
“…[13] Meanwhile, the substantial inflammatory cytokines can further facilitate the progression of IBD, leading to disruption of mucosal barrier damage and loss of tight junction protein (ZO-1). [14] The M1 polarization is regulated by ROS. In the early stage of polarization, macrophages express ROS substantially.…”
Section: Discussionmentioning
confidence: 99%
“…In addition, IAP ameliorated lipopolysaccharide (LPS)-induced inflammation and relocation of ZO-1 at TJ improving epithelial barrier integrity[ 68 ]. Furthermore, Phosphoinositide-3-kinase regulatory subunit 3 (PIK3R3) inhibited the expression of ZO-1 in Caco-2 cells and decreased TJ barrier permeability which was improved after PIK3R3 inhibitor TAT-N 15[ 69 ]. Transcription factor JunD repressed ZO-1 expression through cAMP response element-binding protein-binding (CREB) in colon cancer Caco-2 cells impairing intestinal barrier integrity[ 30 ].…”
Section: Expression Of Zo Proteins In Colon Cancermentioning
confidence: 99%
“…Inflammatory bowel disease (IBD) is non-specific colitis, mainly including ulcerative colitis (UC) and Crohn’s disease (CD), with symptoms such as abdominal pain, diarrhea, and weight loss [ 1 ]. Currently, the prevalence of IBD is on the rise worldwide, with a prevalence of 10–20% in developed countries and more severe in developing countries [ 2 , 3 ]. Pharmacological treatment of IBD in modern society mainly uses drugs such as 5-aminosalicylates and immunosuppressive agents.…”
Section: Introductionmentioning
confidence: 99%